Equity Overview
Price & Market Data
Price: $4.54
Daily Change: -$0.095 / 2.09%
Range: $4.35 - $4.88
Market Cap: $2,648,014
Volume: 38,362
Performance Metrics
1 Week: -17.75%
1 Month: 3.18%
3 Months: -27.33%
6 Months: -72.48%
1 Year: -98.83%
YTD: -73.00%
Company Details
Employees: 10
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.